Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
October 11, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 - - Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers...
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
October 04, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
Option exercise triggers $10 million payment to Voyager, further validating the potential of the TRACER capsid platform Voyager eligible for up to $290 million in associated development, regulatory,...
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
October 03, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
September 27, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
September 07, 2022 07:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
August 04, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting...
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
August 03, 2022 11:30 ET
|
Voyager Therapeutics, Inc.
Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose ...
Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
August 02, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
July 28, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...